Targeting a specific immune pathway to improve treatment for colorectal cancer
Official title: Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy
Funded at University of Miami School of Medicine · NIH-11017737 · Data updated 2026-11-12
This study is looking at a specific immune pathway to see if it can make cancer treatments work better for people with colorectal cancer, and it may involve patients trying out new therapies that could improve their results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 5R00CA248846-05 |
| Project ID | NIH-11017737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with colorectal cancer who have not responded adequately to current immunotherapy treatments.
✕Less likely to help
Patients with early-stage colorectal cancer or those who have not yet undergone immunotherapy may not benefit from this research.
What this research studies
This research investigates the IL-33/ST2 immune pathway to enhance the effectiveness of immunotherapy in colorectal cancer patients. The approach involves understanding how this pathway interacts with existing treatments, particularly those targeting programmed cell death proteins. By utilizing advanced techniques in tumor immunology and bioinformatics, the research aims to identify new therapeutic strategies that could lead to better patient outcomes. Patients may be involved in trials that assess the safety and efficacy of these novel treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for colorectal cancer patients, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting immune pathways for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Van Der Jeught, Kevin — University of Miami School of Medicine
- Study coordinator: Van Der Jeught, Kevin
Related research
Other NIH-funded projects on the same topics.
-
Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer
Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.
-
ST2 nanobodies for colorectal cancer immunotherapy
Aims to create tiny antibody fragments that target ST2 to help diagnose and treat colorectal cancer, potentially helping patients whose disease has spread.
-
Helping the immune system spot and attack colorectal cancer by targeting the immunoproteasome
This project works to make colorectal cancers easier for the immune system to recognize and attack by improving how tumor cells display protein fragments to immune cells.
-
New treatment approach for metastatic colorectal cancer using nanoscale polymers
This study is testing a new treatment for metastatic colorectal cancer that uses tiny particles to help your immune system better recognize and fight tumors, especially if your cancer hasn't responded to other therapies.
-
Improving immune responses against colorectal cancer through targeted therapy
This study is looking at ways to help your immune system better spot and fight colorectal cancer by improving how it recognizes cancer cells, especially for those who haven't had success with current treatments.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.